Literature DB >> 17258302

Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys.

Heather L Kimmel1, Joann A O'Connor, F Ivy Carroll, Leonard L Howell.   

Abstract

Although the behavioral-stimulant and reinforcing effects of cocaine and related psychomotor stimulants have been attributed to their actions at the dopamine transporter (DAT), the reinforcing effectiveness of these compounds varies. The properties that confer these differences are important considerations when developing agonist pharmacotherapies for the treatment of stimulant abuse. The present studies focused on the time course of action and pharmacological specificity of six 3-phenyltropane analogs of cocaine (RTI-112, RTI-126, RTI-150, RTI-171, RTI-177, and RTI-336) by observing their behavioral-stimulant, neurochemical, and reinforcing effects in squirrel monkeys. The faster-onset analogs (RTI-126, RTI-150, and RTI-336), and one of the slower-onset DAT selective analogs (RTI-177 and RTI-171) produced behavioral-stimulant effects, while the slower-onset nonselective analog RTI-112 did not. The time to the peak behavioral-stimulant effect and the peak caudate dopamine levels was strongly correlated, but the area under the curve of the time course of behavioral-stimulant effect and dopamine levels was not correlated. These results suggest that the rate of onset plays a more important role than duration of action in the stimulant effect of these analogs. In addition, the slower-onset nonselective analog (RTI-112) clearly did not exhibit any reinforcing effects while the faster-onset nonselective (RTI-126) and all the DAT-selective analogs showed robust reinforcing effects (RTI-150, and RTI-177) or showed trends towards reinforcing effects (RTI-336 and RTI-171). Hence, there was a general trend for compounds that had a faster onset and/or DAT selectivity to produce significant behavioral-stimulant and reinforcing effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17258302      PMCID: PMC1850383          DOI: 10.1016/j.pbb.2006.12.006

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  54 in total

Review 1.  The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates.

Authors:  L L Howell; K M Wilcox
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

2.  Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

Authors:  L A Marsch; W K Bickel; G J Badger; J P Rathmell; M D Swedberg; B Jonzon; C Norsten-Höög
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

3.  Locomotor stimulant effects of novel phenyltropanes in the mouse.

Authors:  H L Kimmel; F I Carroll; M J Kuhar
Journal:  Drug Alcohol Depend       Date:  2001-12-01       Impact factor: 4.492

4.  Comparative behavioral pharmacology of cocaine and the selective dopamine uptake inhibitor RTI-113 in the squirrel monkey.

Authors:  L L Howell; P W Czoty; M J Kuhar; F I Carrol
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

5.  On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns.

Authors:  K M Wilcox; J K Rowlett; I A Paul; G A Ordway; W L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

6.  Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain.

Authors:  N D Volkow; G J Wang; M W Fischman; R Foltin; J S Fowler; D Franceschi; M Franceschi; J Logan; S J Gatley; C Wong; Y S Ding; R Hitzemann; N Pappas
Journal:  Life Sci       Date:  2000-08-11       Impact factor: 5.037

7.  Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats.

Authors:  L V Panlilio; C W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2000-05       Impact factor: 4.530

8.  A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule.

Authors:  D Stafford; M G LeSage; K C Rice; J R Glowa
Journal:  Drug Alcohol Depend       Date:  2001-03-01       Impact factor: 4.492

9.  Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey.

Authors:  L L Howell; L D Byrd
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

Review 10.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

View more
  42 in total

1.  The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Authors:  K S Murnane; H L Kimmel; K C Rice; L L Howell
Journal:  Horm Behav       Date:  2011-12-14       Impact factor: 3.587

2.  Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates.

Authors:  Paul W Czoty; Jennifer L Martelle; F Ivy Carroll; Michael A Nader
Journal:  Pharmacol Biochem Behav       Date:  2010-05-24       Impact factor: 3.533

Review 3.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

4.  Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter.

Authors:  Chunyang Jin; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

Authors:  Leonard Lee Howell; Kevin Sean Murnane
Journal:  J Pharmacol Exp Ther       Date:  2011-02-11       Impact factor: 4.030

6.  Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription.

Authors:  Yaxia Yuan; Xiaoqin Huang; Jun Zhu; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2016-10-14       Impact factor: 3.808

7.  Increased vulnerability to cocaine in mice lacking dopamine D3 receptors.

Authors:  Rui Song; Hai-Ying Zhang; Xia Li; Guo-Hua Bi; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

8.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

9.  Effects of histamine H(3) receptor activation on the behavioral-stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys.

Authors:  Matthew L Banks; Daniel F Manvich; Rayna M Bauzo; Leonard L Howell
Journal:  Pharmacology       Date:  2009-01-15       Impact factor: 2.547

10.  Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey.

Authors:  Heather L Kimmel; Daniel F Manvich; Bruce E Blough; S Stevens Negus; Leonard L Howell
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.